Brief: Appili Therapeutics Inc. Expands Preseco Clinical Trial Of Avigan®/Reeqonus™ For Mild-To-Moderate Covid-19 Patients Into Mexico And Brazil
17/06/2021 12:59
June 17 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS INC. EXPANDS PRESECO CLINICAL TRIAL OF
AVIGAN®/REEQONUS™ FOR MILD-TO-MODERATE COVID-19 PATIENTS INTO
MEXICO AND BRAZIL
* APPILI THERAPEUTICS INC - AS PART OF EXPANSION AND
PRIORITIZATION OF PRESECO TREATMENT STUDY, APPILI HAS ENDED ITS
CONTROL TRIAL
* APPILI THERAPEUTICS INC - ALSO PLANNED A PHASE 3 STUDY
PEPCO
(POST EXPOSURE PROPHYLAXIS FOR COVID-19)
Source text for Eikon: ID:nBwb193Rba
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez